This database contains 1433 studies, archived under the term: ""
Click here to filter this large number of results.
A phase 3 trial of semagacestat for treatment of Alzheimer’s disease
Doody, Rachelle S.,
Raman, Rema,
Farlow, Martin,
Iwatsubo, Takeshi,
Vellas, Bruno,
Joffe, Steven,
Kieburtz, Karl,
He, Feng,
Sun, Xiaoying,
Thomas, Ronald G.,
Aisen, Paul S,
Siemers, Eric,
Sethuraman, Gopalan,
Mohs, Richard
Background: Alzheimer’s disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer’s disease.; Methods: We conducted a double-blind, placebo-controlled trial in which 1537 patients […]
The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline
Donohue, Michael C.,
Sperling, Reisa A.,
Salmon, David P.,
Rentz, Dorene M.,
Raman, Rema,
Thomas, Ronald G.,
Weiner, Michael,
Aisen, Paul S
Importance: As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes. Objective: To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evidence of AD pathology using the ADCS Preclinical Alzheimer Cognitive Composite (ADCS-PACC). The […]
Effects of multicomponent exercise on spatial-temporal gait parameters among the elderly with amnestic mild cognitive impairment (aMCI): preliminary results from a randomized controlled trial (RCT)
Doi, Takehiko,
Makizako, Hyuma,
Shimada, Hiroyuki,
Yoshida, Daisuke,
Tsutsumimoto, Kota,
Sawa, Ryuichi,
Misu, Shogo,
Suzuki, Takao
Exercise training has been shown to increase physical function in the elderly. However, the effects of exercise on elderly individuals with amnestic aMCI are unclear. The aim of this RCT was to investigate the effect of multicomponent exercise on gait in the elderly. Fifty elderly individuals with aMCI (age: 65-92 years) participated in the study […]
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Dodel, Richard,
Rominger, Axel,
Bartenstein, Peter,
Barkhof, Frederik,
Blennow, Kaj,
Förster, Stefan,
Winter, Yaroslav,
Bach, Jan-Philipp,
Popp, Julius,
Alferink, Judith,
Wiltfang, Jens,
Buerger, Katharina,
Otto, Markus,
Antuono, Piero,
Jacoby, Michael,
Richter, Ralph,
Stevens, James,
Melamed, Isaac,
Goldstein, Jerome,
Haag, Stefan,
Wietek, Stefan,
Farlow, Martin,
Jessen, Frank
Background: Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer’s disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.; Methods: We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA and five in Germany. Participants with probable Alzheimer’s […]
Efectos del Modelo de Atención Centrado en la Persona en la calidad de vida de personas con deterioro cognitivo de centros gerontológicos. = Effects from the Person Centered-Care Model on quality of life of cognitive impaired persons from gerontological centers
Díaz-Veiga, Pura,
Sancho, Mayte,
García, Álvaro,
Rivas, Esther,
Abad, Elixabet,
Suárez, Nerea,
Mondragón, Gabriela,
Buiza, Cristina,
Orbegozo, Ana,
Yanguas, Javier
Introduction: The Model of Person Centered Care has attracted increasing interest for use in gerontology centers. Therefore, the contributions about its impact are scarce in our context. The objective of this paper is to establish the impact that the interventions associated with the Model of Person Centered Care in the «Etxean Ondo» Project have on […]
Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study
del Ser, Teodoro,
Steinwachs, Klaus C.,
Gertz, Hermann J.,
Andrés, María V.,
Gómez-Carrillo, Belén,
Medina, Miguel,
Vericat, Joan A.,
Redondo, Pilar,
Fleet, David,
Leon, Teresa
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, […]
The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: a randomised controlled study
de Waal, Hanneke,
Stam, Cornelis J.,
Lansbergen, Marieke M.,
Wieggers, Rico L.,
Kamphuis, Patrick J. G. H.,
Scheltens, Philip,
Maestú, Fernando,
van Straaten, Elisabeth C. W.
Background: Synaptic loss is a major hallmark of Alzheimer’s disease (AD). Disturbed organisation of large-scale functional brain networks in AD might reflect synaptic loss and disrupted neuronal communication. The medical food Souvenaid, containing the specific nutrient combination Fortasyn Connect, is designed to enhance synapse formation and function and has been shown to improve memory performance […]
Do patients diagnosed with Alzheimer’s disease benefit from a psycho-educational programme for family caregivers? A randomised controlled study
de Rotrou, Jocelyne,
Cantegreil, Inge,
Faucounau, Véronique,
Wenisch, Emilie,
Chausson, Catherine,
Jegou, David,
Grabar, Sophie,
Rigaud, Anne-Sophie
Objective: The Aide dans la Maladie d’Alzheimer (AIDMA) study was conducted to determine whether a psycho-educational programme (PEP) for primary caregivers in addition to standard anti-dementia drugs for patients improves caregivers’ psychological condition and patients’ activities of daily life.; Method: Multicentre randomised controlled intervention trial. One hundred and sixty-seven dyads ‘patient-caregiver’ were recruited from 15 […]